Limnopharma was created in March 2019 with the aim of developing new therapies for different retina diseases, which affect more than 200 million people worldwide and for which current treatments either do not exist or are extremely expensive and invasive. The diseases initially targeted are Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP).
Limnopharma aims to carry out the early stages of the development of potential medications, specifically completing the preclinical phase and clinical phases I and II of our compounds for the different treatments, and then obtain approval to start clinical trials with the drugs.
Limnopharma is currently focusing on the development and validation of therapies for ophthalmic diseases. This has been possible thanks to the potential demonstrated by the LIM21 and LIM109 molecules, as well as other specific structurally-related compounds, in animal models of Age-Related Macular Degeneration and Retinitis Pigmentosa.
It is hoped that the necessary studies can progressively be conducted to validate therapies for related diseases, such as Diabetic Retinopathy or Stargardt’s disease. The LIM21 and LIM109 molecules belong to a family of compounds designed in the laboratory of Dr. Juan Carlos Morales due to their neuroprotective and anti-inflammatory properties.
For this reason, the Limnopharma team plans to study the viability of some of these molecules for the treatment of pathologies in which these processes play an important role. These medium- to long-term projects are based on preliminary experiments in Huntington’s disease and Multiple Sclerosis models.